WCM Investment Management
LGND icon

WCM Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

WCM Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.6M Sell
44,658
-963
-2% -$191K 0.02% 163
2025
Q4 		$8.68M Buy
+45,621
New +$8.77M 0.02% 158
2021
Q4 		– Sell
-48,199
Closed -$4.19M – 211
2021
Q3 		$4.19M Buy
48,199
+236
+0.5% +$18.3K 0.01% 149
2021
Q2 		$3.92M Buy
47,963
+1,755
+4% +$146K 0.01% 145
2021
Q1 		$4.39M Sell
46,208
-62,225
-57% -$5.88M 0.01% 140
2020
Q4 		$6.73M Buy
108,433
+46,225
+74% +$2.64M 0.02% 133
2020
Q3 		$3.7M Buy
62,208
+3,886
+7% +$265K 0.01% 144
2020
Q2 		$4.07M Buy
58,322
+4,740
+9% +$300K 0.02% 136
2020
Q1 		$2.43M Buy
53,582
+15,355
+40% +$870K 0.01% 144
2019
Q4 		$2.49M Buy
38,227
+28,880
+309% +$1.93M 0.01% 140
2019
Q3 		$580K Hold
9,347
– – ﹤0.01% 139
2019
Q2 		$666K Buy
9,347
+4,772
+104% +$351K ﹤0.01% 138
2019
Q1 		$359K Buy
+4,575
New +$347K ﹤0.01% 138

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

WCM Investment Management's LGND Position: Q1 2026 in Review

WCM Investment Management reduced its Ligand Pharmaceuticals (LGND) stake by 2.1% in Q1 2026, selling an estimated $191K and leaving 44,658 shares worth $8.6M. The position accounts for 0.02% of the portfolio, ranked #163.

WCM Investment Management first reported a position in LGND in Q1 2019 and has held it in 13 quarters since. The position peaked at $8.68M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • WCM Investment Management held 44,658 shares of Ligand Pharmaceuticals worth $8.6M as of Q1 2026.
  • WCM Investment Management sold 963 Ligand Pharmaceuticals shares in Q1 2026, an estimated $191K.
  • Ligand Pharmaceuticals made up 0.02% of WCM Investment Management's portfolio in Q1 2026, its #163 holding.
  • WCM Investment Management first reported a position in Ligand Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
  • WCM Investment Management's Ligand Pharmaceuticals position peaked at $8.68M in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on WCM Investment Management's 13F filing for Q1 2026, filed 7 May 2026.